FilingReader Intelligence
Zydus facility receives favorable US FDA assessment
July 17, 2025 at 05:16 PM UTC•By FilingReader AI
Zydus Lifesciences announced the successful closure of a USFDA Remote Regulatory Assessment at its Matoda, Gujarat facility, with no observations noted and a recommendation for approval for Atorvastatin Calcium Tablets.
This news follows the company's strong financial performance in FY2025, with revenues up 19% to ₹232.4 billion.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
Supplementary Source Documents
BSE:ZYDUSLIFE•Bombay Stock Exchange
News Alerts
Get instant email alerts when Zydus Lifesciences publishes news
Free account required • Unsubscribe anytime